{"transactions":[{"id":1100086,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100085,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100084,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.36,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100083,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.45,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100082,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.7,"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100081,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":9.9,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100080,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100079,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100078,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.36,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100077,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.45,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100076,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.7,"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100075,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":9.9,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100074,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":8.8,"underlying":"Common Stock","underlying_shares":2325},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100073,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4650,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":6.4,"underlying":"Common Stock","underlying_shares":4650},"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100072,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":57292,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement, each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100071,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"other","planned":false,"acquired":false,"shares":5208,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for the Offer Price."}],"balance_after":57292,"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100070,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":57292,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement, each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1100069,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T17:03:30.000Z","date":"2025-06-25","kind":"other","planned":false,"acquired":false,"shares":27377,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for the Offer Price."}],"balance_after":57292,"source":{"system":"sec-edgar","filing":"0000950170-25-091008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025091008/ownership.xml","form_type":"4"}},{"id":1163298,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T16:30:12.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 30, 2025, the Reporting Person was granted 62,500 Restricted Stock Units (the \"Award\").  The Award vests in equal monthly installments over the 12 months from the date of grant."}],"balance_after":62500,"source":{"system":"sec-edgar","filing":"0000950170-25-061118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025061118/ownership.xml","form_type":"4"}},{"id":1163297,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T16:30:12.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 30, 2025, the Reporting Person was granted 62,500 Restricted Stock Units (the \"Award\").  The Award vests in equal monthly installments over the 12 months from the date of grant."}],"balance_after":84669,"source":{"system":"sec-edgar","filing":"0000950170-25-061118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025061118/ownership.xml","form_type":"4"}},{"id":1289310,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-31T17:00:06.000Z","date":"2025-01-30","kind":"purchase","planned":false,"acquired":true,"shares":19610,"price":1.06,"value":20786.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $1.06, and the range of prices were between $0.97 and $1.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each price will be provided."}],"balance_after":22169,"source":{"system":"sec-edgar","filing":"0000950170-25-011850","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017025011850/ownership.xml","form_type":"4"}},{"id":1506941,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-21T16:22:15.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":60000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-19","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-062923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017024062923/ownership.xml","form_type":"4"}},{"id":1510934,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T16:45:18.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of\nStockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the\nCompany's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-061771","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000095017024061771/ownership.xml","form_type":"4"}},{"id":1808369,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-14T16:13:51.000Z","date":"2023-08-10","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant, subject to the Reporting Person's continuous service."}],"balance_after":15000,"derivative":{"exercise_price":1.36,"expiration_date":"2033-08-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-045620","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919123045620/doc4.xml","form_type":"4"}},{"id":1857037,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T16:46:44.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":1.45,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-036753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919123036753/doc4.xml","form_type":"4"}},{"id":2235666,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T16:21:00.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":90000,"derivative":{"exercise_price":0.27,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-22-035883","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919122035883/doc4.xml","form_type":"4"}},{"id":2667973,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T16:39:48.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":40000,"derivative":{"exercise_price":0.9877,"expiration_date":"2031-06-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-040612","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919121040612/doc4.xml","form_type":"4"}},{"id":2893326,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":78036,"kind":"person","name":"Huang Alice Shih-hou","position":1,"cik":"0001842618","reported_name":"Huang Alice Shih-hou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":2,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-27T20:32:07.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vest one year following the date of grant and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested three years following the date of grant, subject to the reporting person's continuous service."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Dr. Baltimore may be imputed to beneficially own the shares exercisable under the option awarded to his spouse, Dr. Huang."}],"balance_after":80000,"derivative":{"exercise_price":1.55,"expiration_date":"2031-01-26","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-21-005784","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919121005784/doc4.xml","form_type":"4"}},{"id":3104114,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T16:37:23.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":23250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":23250,"derivative":{"exercise_price":0.88,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":23250},"source":{"system":"sec-edgar","filing":"0001209191-20-037948","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919120037948/doc4.xml","form_type":"4"}},{"id":3393585,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-15T16:40:31.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":46500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":46500,"derivative":{"exercise_price":0.64,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":46500},"source":{"system":"sec-edgar","filing":"0001209191-19-053159","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919119053159/doc4.xml","form_type":"4"}},{"id":3562611,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:17:58.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Not Applicable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."}],"balance_after":0,"derivative":{"exercise_price":1.31,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-023689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023689/doc4.xml","form_type":"4"}},{"id":3562610,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:17:58.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Not Applicable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."}],"balance_after":0,"derivative":{"exercise_price":4.05,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-023689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023689/doc4.xml","form_type":"4"}},{"id":3562609,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:17:58.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":5.6,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-023689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023689/doc4.xml","form_type":"4"}},{"id":3562608,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:17:58.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":4281,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":1.23,"underlying":"Common Stock","underlying_shares":4281},"source":{"system":"sec-edgar","filing":"0001209191-19-023689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023689/doc4.xml","form_type":"4"}},{"id":3562607,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:17:58.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":3058,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":1.48,"underlying":"Common Stock","underlying_shares":3058},"source":{"system":"sec-edgar","filing":"0001209191-19-023689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023689/doc4.xml","form_type":"4"}},{"id":3562606,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-04T17:17:58.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":78287,"price":5.85,"value":457978.95,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.  In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement (\"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-023689","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023689/doc4.xml","form_type":"4"}},{"id":3701865,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-07T20:16:30.000Z","date":"2019-01-03","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares underlying the option will vest on January 3, 2020."}],"balance_after":12500,"derivative":{"exercise_price":1.31,"expiration_date":"2029-01-03","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-002658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119002658/doc4.xml","form_type":"4"}},{"id":3766527,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":4583,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The cancelled option provided for vesting in twelve equally monthly installments, such that the option would be fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occurred first."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":8.76,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":4583},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766526,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":8.52,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766525,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":17.4,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766524,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":3051,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":74.4,"expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":3051},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766523,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":120.24,"expiration_date":"2025-06-08","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766522,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":416,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":74.64,"expiration_date":"2024-05-21","underlying":"Common Stock","underlying_shares":416},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766521,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":74.64,"expiration_date":"2024-05-21","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766520,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":111.84,"expiration_date":"2023-06-09","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766519,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":416,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":111.84,"expiration_date":"2023-06-09","underlying":"Common Stock","underlying_shares":416},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766518,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":31.92,"expiration_date":"2022-02-08","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766517,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":625,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":31.92,"expiration_date":"2022-02-08","underlying":"Common Stock","underlying_shares":625},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766516,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":20.88,"expiration_date":"2021-01-02","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766515,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":625,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":20.88,"expiration_date":"2021-01-02","underlying":"Common Stock","underlying_shares":625},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766514,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":4.56,"expiration_date":"2019-12-01","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766513,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":625,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":4.56,"expiration_date":"2019-12-01","underlying":"Common Stock","underlying_shares":625},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766512,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1875,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":4.56,"expiration_date":"2019-01-01","underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766511,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":10625,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":4.56,"expiration_date":"2019-01-01","underlying":"Common Stock","underlying_shares":10625},"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3766510,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-13T17:35:37.000Z","date":"2018-11-12","kind":"grant","acquired":true,"shares":40339,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I.  The RSUs vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":44131,"source":{"system":"sec-edgar","filing":"0001209191-18-058350","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118058350/doc4.xml","form_type":"4"}},{"id":3904844,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T16:29:13.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in twelve equally monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first."}],"balance_after":55000,"derivative":{"exercise_price":0.73,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-18-035695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118035695/doc4.xml","form_type":"4"}},{"id":3923751,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-21T16:36:23.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in twelve equal monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first."}],"balance_after":75000,"derivative":{"exercise_price":0.71,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-18-031880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919118031880/doc4.xml","form_type":"4"}},{"id":129460,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-05-01T22:26:19.000Z","date":"2018-04-27","kind":"grant","acquired":true,"shares":1127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately.  Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.  Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule."}],"balance_after":32286,"source":{"system":"sec-edgar","filing":"0001127602-18-015802","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760218015802/form4.xml","form_type":"4"}},{"id":4104184,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-08T20:26:13.000Z","date":"2018-01-04","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares underlying the option will vest on January 4, 2019."}],"balance_after":12500,"derivative":{"exercise_price":4.05,"expiration_date":"2028-01-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-18-002812","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919118002812/doc4.xml","form_type":"4"}},{"id":4140227,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-06T19:43:16.000Z","date":"2017-12-04","kind":"grant","acquired":true,"shares":60674,"price":0.89,"value":53999.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted Stock Units (RSU) issued in lieu of 2018 annual retainer and meeting fees of $54,000.  The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus."}],"balance_after":60674,"source":{"system":"sec-edgar","filing":"0001209191-17-064274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919117064274/doc4.xml","form_type":"4"}},{"id":139882,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-06-02T23:21:26.000Z","date":"2017-05-31","kind":"sale","acquired":false,"shares":3700,"price":153.93,"value":569541.0,"ownership":{"direct":true},"balance_after":31159,"source":{"system":"sec-edgar","filing":"0001127602-17-020401","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760217020401/form4.xml","form_type":"4"}},{"id":4295453,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Option to Buy)","published_at":"2017-06-02T16:38:29.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in twelve equal monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occurs first."}],"balance_after":30000,"derivative":{"exercise_price":1.45,"expiration_date":"2027-05-31","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-17-037288","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185858/000120919117037288/doc4.xml","form_type":"4"}},{"id":141008,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-05-04T00:13:58.000Z","date":"2017-05-01","kind":"grant","acquired":true,"shares":1230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately.  Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.  Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule."}],"balance_after":34859,"source":{"system":"sec-edgar","filing":"0001127602-17-016727","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760217016727/form4.xml","form_type":"4"}},{"id":4496310,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-01-06T21:07:14.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will become fully vested on January 4, 2018, subject to the Reporting Person's continuous service through such\ndate."}],"balance_after":10000,"derivative":{"exercise_price":5.6,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-002803","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919117002803/doc4.xml","form_type":"4"}},{"id":153080,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2016-05-05T23:45:41.000Z","date":"2016-05-03","kind":"grant","acquired":true,"shares":1279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately.  Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.  Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule."}],"balance_after":33629,"source":{"system":"sec-edgar","filing":"0001127602-16-051272","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760216051272/form4.xml","form_type":"4"}},{"id":153259,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-05-03T23:12:58.000Z","date":"2016-04-29","kind":"sale","acquired":false,"shares":3312,"price":157.2113,"value":520683.8256,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The price reported is an average price. The prices ranged from $157.14 to $157.28 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer."}],"balance_after":32350,"source":{"system":"sec-edgar","filing":"0000899243-16-019139","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924316019139/doc4.xml","form_type":"4"}},{"id":154211,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Nqso (Right to Buy)","published_at":"2016-03-31T22:01:03.000Z","date":"2016-03-30","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":50.44,"exercise_date":"2009-04-28","expiration_date":"2016-04-28","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-16-047970","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760216047970/form4.xml","form_type":"4"}},{"id":154210,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2016-03-31T22:01:03.000Z","date":"2016-03-30","kind":"tax_withholding","acquired":false,"shares":1688,"price":149.49,"value":252339.12,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Non-market exercise of 5,000 stock options expiring April 28, 2016 wherein 1,688 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price, with the remaining shares delivered to the reporting person."}],"balance_after":35662,"source":{"system":"sec-edgar","filing":"0001127602-16-047970","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760216047970/form4.xml","form_type":"4"}},{"id":154209,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2016-03-31T22:01:03.000Z","date":"2016-03-30","kind":"exercise","acquired":true,"shares":5000,"price":50.44,"value":252200.0,"ownership":{"direct":true},"balance_after":37350,"source":{"system":"sec-edgar","filing":"0001127602-16-047970","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760216047970/form4.xml","form_type":"4"}},{"id":164495,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2015-04-28T22:44:00.000Z","date":"2015-04-24","kind":"grant","acquired":true,"shares":1191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately.  Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.  Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule."}],"balance_after":32350,"source":{"system":"sec-edgar","filing":"0001127602-15-015443","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760215015443/form4.xml","form_type":"4"}},{"id":166101,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2015-03-04T01:55:44.000Z","date":"2015-03-02","kind":"sale","acquired":false,"shares":3647,"price":158.7637,"value":579011.2139,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is an average price.  The prices ranged from $158.74 to $158.791 per share.  Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer."}],"balance_after":31159,"source":{"system":"sec-edgar","filing":"0001127602-15-009820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760215009820/form4.xml","form_type":"4"}},{"id":166360,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Nqso (Right to Buy)","published_at":"2015-02-23T21:13:51.000Z","date":"2015-02-19","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":42.13,"exercise_date":"2008-04-29","expiration_date":"2015-04-29","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-15-007689","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760215007689/form4.xml","form_type":"4"}},{"id":166359,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2015-02-23T21:13:51.000Z","date":"2015-02-19","kind":"tax_withholding","acquired":false,"shares":1353,"price":155.78,"value":210770.34,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Non-market exercise of 5,000 stock options expiring April 29, 2015 wherein 1,353 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price, with the remaining shares delivered to the reporting person."}],"balance_after":34806,"source":{"system":"sec-edgar","filing":"0001127602-15-007689","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760215007689/form4.xml","form_type":"4"}},{"id":166358,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2015-02-23T21:13:51.000Z","date":"2015-02-19","kind":"exercise","acquired":true,"shares":5000,"price":42.13,"value":210650.0,"ownership":{"direct":true},"balance_after":36159,"source":{"system":"sec-edgar","filing":"0001127602-15-007689","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760215007689/form4.xml","form_type":"4"}},{"id":174333,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2014-04-29T20:58:35.000Z","date":"2014-04-25","kind":"grant","acquired":true,"shares":1795,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately.  Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.  Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule."}],"balance_after":31159,"source":{"system":"sec-edgar","filing":"0001127602-14-015481","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760214015481/form4.xml","form_type":"4"}},{"id":175930,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Nqso (Right to Buy)","published_at":"2014-02-27T01:28:10.000Z","date":"2014-02-26","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":62.55,"exercise_date":"2007-04-26","expiration_date":"2014-04-26","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-14-008758","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760214008758/form4.xml","form_type":"4"}},{"id":175929,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2014-02-27T01:28:10.000Z","date":"2014-02-26","kind":"tax_withholding","acquired":false,"shares":2515,"price":124.36,"value":312765.4,"ownership":{"direct":true},"balance_after":29364,"source":{"system":"sec-edgar","filing":"0001127602-14-008758","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760214008758/form4.xml","form_type":"4"}},{"id":175928,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2014-02-27T01:28:10.000Z","date":"2014-02-26","kind":"exercise","acquired":true,"shares":5000,"price":62.55,"value":312750.0,"ownership":{"direct":true},"balance_after":31879,"source":{"system":"sec-edgar","filing":"0001127602-14-008758","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760214008758/form4.xml","form_type":"4"}},{"id":181131,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2013-08-30T21:36:18.000Z","date":"2013-08-29","kind":"gift","acquired":false,"shares":910,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":26879,"source":{"system":"sec-edgar","filing":"0001127602-13-026332","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760213026332/form4.xml","form_type":"4"}},{"id":181130,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2013-08-30T21:36:18.000Z","date":"2013-08-28","kind":"sale","acquired":false,"shares":4582,"price":109.66,"value":502462.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is an average price.  The prices ranged from $109.61 to $109.70 per share.  Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer."}],"balance_after":27789,"source":{"system":"sec-edgar","filing":"0001127602-13-026332","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760213026332/form4.xml","form_type":"4"}},{"id":184981,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2013-04-30T21:31:33.000Z","date":"2013-04-26","kind":"grant","acquired":true,"shares":1845,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and vested immediately.  Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.  Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule."}],"balance_after":32371,"source":{"system":"sec-edgar","filing":"0001127602-13-014787","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760213014787/form4.xml","form_type":"4"}},{"id":186497,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Nqso (Right to Buy)","published_at":"2013-03-01T22:31:44.000Z","date":"2013-02-28","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":74.89,"exercise_date":"2006-03-15","expiration_date":"2013-03-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-13-008845","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760213008845/form4.xml","form_type":"4"}},{"id":186496,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2013-03-01T22:31:44.000Z","date":"2013-02-28","kind":"sale","acquired":false,"shares":886,"price":92.94,"value":82344.84,"ownership":{"direct":true},"balance_after":30526,"source":{"system":"sec-edgar","filing":"0001127602-13-008845","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760213008845/form4.xml","form_type":"4"}},{"id":186495,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2013-03-01T22:31:44.000Z","date":"2013-02-28","kind":"tax_withholding","acquired":false,"shares":4114,"price":91.03,"value":374497.42,"ownership":{"direct":true},"balance_after":31412,"source":{"system":"sec-edgar","filing":"0001127602-13-008845","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760213008845/form4.xml","form_type":"4"}},{"id":186494,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2013-03-01T22:31:44.000Z","date":"2013-02-28","kind":"exercise","acquired":true,"shares":5000,"price":74.89,"value":374450.0,"ownership":{"direct":true},"balance_after":35526,"source":{"system":"sec-edgar","filing":"0001127602-13-008845","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760213008845/form4.xml","form_type":"4"}},{"id":189098,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Nqso (Right to Buy)","published_at":"2012-12-12T23:40:57.000Z","date":"2012-12-10","kind":"exercise","acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":50.78,"exercise_date":"2003-01-27","expiration_date":"2013-01-27","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001127602-12-033766","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212033766/form4.xml","form_type":"4"}},{"id":189097,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2012-12-12T23:40:57.000Z","date":"2012-12-10","kind":"sale","acquired":false,"shares":6800,"price":89.003,"value":605220.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is an average price.  The prices ranged from $88.99 to $89.025 per share.  Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer."}],"balance_after":30526,"source":{"system":"sec-edgar","filing":"0001127602-12-033766","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212033766/form4.xml","form_type":"4"}},{"id":189096,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2012-12-12T23:40:57.000Z","date":"2012-12-10","kind":"tax_withholding","acquired":false,"shares":9200,"price":88.32,"value":812544.0,"ownership":{"direct":true},"balance_after":37326,"source":{"system":"sec-edgar","filing":"0001127602-12-033766","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212033766/form4.xml","form_type":"4"}},{"id":189095,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2012-12-12T23:40:57.000Z","date":"2012-12-10","kind":"exercise","acquired":true,"shares":16000,"price":50.78,"value":812480.0,"ownership":{"direct":true},"balance_after":46526,"source":{"system":"sec-edgar","filing":"0001127602-12-033766","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212033766/form4.xml","form_type":"4"}},{"id":194040,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Nqso (Right to Buy)","published_at":"2012-05-01T23:34:00.000Z","date":"2012-04-27","kind":"grant","acquired":true,"shares":5000,"price":71.64,"value":358200.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":71.64,"exercise_date":"2012-04-27","expiration_date":"2022-04-27","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-12-015213","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212015213/form4.xml","form_type":"4"}},{"id":194039,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2012-05-01T23:34:00.000Z","date":"2012-04-27","kind":"grant","acquired":true,"shares":1395,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the \"Director Program\") and vested immediately because the director has three years or more of prior continuous service as a director.  Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.  Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule."}],"balance_after":30526,"source":{"system":"sec-edgar","filing":"0001127602-12-015213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212015213/form4.xml","form_type":"4"}},{"id":194938,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Nqso (Right to Buy)","published_at":"2012-03-12T23:50:32.000Z","date":"2012-03-08","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":58.61,"exercise_date":"2005-03-15","expiration_date":"2012-03-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-12-010447","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212010447/form4.xml","form_type":"4"}},{"id":194937,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2012-03-12T23:50:32.000Z","date":"2012-03-08","kind":"tax_withholding","acquired":false,"shares":4378,"price":66.95,"value":293107.1,"ownership":{"direct":true},"balance_after":29131,"source":{"system":"sec-edgar","filing":"0001127602-12-010447","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212010447/form4.xml","form_type":"4"}},{"id":194936,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2012-03-12T23:50:32.000Z","date":"2012-03-08","kind":"exercise","acquired":true,"shares":5000,"price":58.61,"value":293050.0,"ownership":{"direct":true},"balance_after":33509,"source":{"system":"sec-edgar","filing":"0001127602-12-010447","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212010447/form4.xml","form_type":"4"}},{"id":197425,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Nqso (Right to Buy)","published_at":"2011-12-22T21:36:49.000Z","date":"2011-12-22","kind":"exercise","acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":56.3,"exercise_date":"2002-01-28","expiration_date":"2012-01-28","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001127602-11-033098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760211033098/form4.xml","form_type":"4"}},{"id":197424,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2011-12-22T21:36:49.000Z","date":"2011-12-22","kind":"tax_withholding","acquired":false,"shares":14267,"price":63.14,"value":900818.38,"ownership":{"direct":true},"balance_after":28509,"source":{"system":"sec-edgar","filing":"0001127602-11-033098","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760211033098/form4.xml","form_type":"4"}},{"id":197423,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2011-12-22T21:36:49.000Z","date":"2011-12-22","kind":"exercise","acquired":true,"shares":16000,"price":56.3,"value":900800.0,"ownership":{"direct":true},"balance_after":42776,"source":{"system":"sec-edgar","filing":"0001127602-11-033098","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760211033098/form4.xml","form_type":"4"}},{"id":203537,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Nqso (Right to Buy)","published_at":"2011-04-28T00:03:23.000Z","date":"2011-04-25","kind":"grant","acquired":true,"shares":5000,"price":54.69,"value":273450.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":54.69,"exercise_date":"2011-04-25","expiration_date":"2021-04-25","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-11-013850","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760211013850/form4.xml","form_type":"4"}},{"id":203536,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Common Stock","published_at":"2011-04-28T00:03:23.000Z","date":"2011-04-25","kind":"grant","acquired":true,"shares":1828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director."}],"balance_after":26776,"source":{"system":"sec-edgar","filing":"0001127602-11-013850","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760211013850/form4.xml","form_type":"4"}},{"id":214416,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12135,"kind":"person","name":"BALTIMORE DAVID","position":1,"cik":"0001185858","reported_name":"BALTIMORE DAVID","relationship":{"director":true}}],"security":"Nqso (Right to Buy)","published_at":"2010-04-28T22:33:35.000Z","date":"2010-04-26","kind":"grant","acquired":true,"shares":5000,"price":58.43,"value":292150.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":58.43,"exercise_date":"2010-04-26","expiration_date":"2020-04-26","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-10-012360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760210012360/form4.xml","form_type":"4"}}],"next_cursor":"2010-04-28T22:33:35.000000Z,214416"}